weight loss drugs

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services. • Eli Lilly...

Hims & Hers Health reported first-quarter financial results Monday after market close. • Hims & Hers Health shares are retreating from recent levels. Why is HIMS stock dropping? Here are the key highlights. Hims & Hers Q1 Financials Hims & Hers reported first-quarter...

The U.S. Food and Drug Administration (FDA) on Thursday approved a higher-dose version of Novo Nordisk A/S’ (NYSE:NVO) blockbuster weight-loss drug, Wegovy, marking an expansion of its treatment portfolio for adults with obesity. • Novo Nordisk shares are experiencing downward...

Super Bowl LX aired on Sunday, Feb. 8, 2026, and the Seattle Seahawks defeated the New England Patriots 29-13, in a game that saw 30 of the 42 total points scored in the fourth quarter. The game also featured dozens of commercials advertising products and showcasing new movies and television shows...

Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ahead for NVO stock? The class action complaint, filed in the U.S. District Court,...

Linda Yaccarino may have a resume that many people around the world envy. In the past two years, Yaccarino has worked for Elon Musk and is now Tom Brady's boss. • Novo Nordisk stock is facing resistance. Why is NVO stock trading lower? Tom Brady Joins Telehealth Startup eMed In 23 seasons in...

Major U.S. indexes closed higher on Monday, with the Dow Jones Industrial Average rising 0.47% to 48,362.68. The S&P 500 advanced 0.6% to 6,878.49, while the Nasdaq added 0.5% to finish at 23,428.82. These are the top stocks that gained the attention of retail traders and investors through the...

Restaurant giant McDonald's Corporation (NYSE:MCD) could show the importance of value meals and new product launches when the company announces third-quarter financial results on Wednesday before market open. • See what the experts say about MCD stock here. Here are the earnings estimates, analyst...

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook. Obesity & Heart...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading. The agency's review found that the video misbrands the drugs by underplaying serious health risks...

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1...

Former X CEO Linda Yaccarino is celebrating her new company with a "milestone day" Monday. Here's the latest for the former X CEO after moving on from the social media company owned by Elon Musk after two years. What Happened: After years of helping boost X as a news source and place for...

Telehealth darling Hims & Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable. But is the plunge a chance to swipe right on the dip, or should investors ghost the stock altogether? The high...

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...